Results of time series (ARIMA) modelling of effects of policy initiatives on smoking cessation medication sales
| B | SE | T ratio | p Value | |
|---|---|---|---|---|
| *The power to estimate this parameter was limited by the fact that there were very few data points before the event. | ||||
| GSL, general sales; NRT, nicotine replacement therapy; OTC, over-the-counter; SE, standard error | ||||
| Total | ||||
| Year | 28504.5 | 16508.1 | 1.73 | 0.09 |
| 2 mg gum on GSL* | 9733.1 | 29994.3 | 0.32 | 0.75 |
| Bupropion reimbursed | 101629.3 | 25914.8 | 3.92 | 0.0003 |
| NRT reimbursed | 80800.9 | 34188.0 | 2.36 | 0.02 |
| Other NRT on GSL | 55031.5 | 35536.8 | 1.55 | 0.13 |
| Lozenge available | 72621.8 | 29252.2 | 2.48 | 0.02 |
| Prescription nicotine replacement | ||||
| Year | −8078.1 | 15372.6 | −0.53 | 0.60 |
| 2 mg gum on GSL* | 2406.6 | 27897.2 | 0.09 | 0.93 |
| Bupropion reimbursed | 14891.4 | 24037.7 | 0.62 | 0.54 |
| NRT reimbursed | 99343.8 | 31982.9 | 3.11 | 0.003 |
| Other NRT on GSL | 81004.0 | 33296.5 | 2.43 | 0.20 |
| Lozenge available | 100575.1 | 27205.7 | 3.69 | 0.0007 |
| OTC nicotine replacement | ||||
| Year | 18452.2 | 7234.06 | 2.55 | 0.014 |
| 2 mg gum on GSL* | −18351.4 | 13315.1 | −1.38 | 0.18 |
| Bupropion reimbursed | 8906.1 | 11783.0 | 0.76 | 0.45 |
| NRT reimbursed | 19005.0 | 14493.6 | 1.31 | 0.20 |
| Other NRT on GSL | 14164.7 | 14866.4 | 0.95 | 0.35 |
| Lozenge available | 24831.0 | 12998.16 | 1.91 | 0.06 |